RxDoctor Payments Data

Stewart Keller, DO

Psychiatry · Fort Worth, TXNPI 1881647295

Payments from drug & device makers

$1,097in general payments, 2019–2025

Across 77 payments — averaging $14.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$477
  • Sunovion Pharmaceuticals Inc.$183
  • Alkermes, Inc.$153
  • Otsuka America Pharmaceutical, Inc.$94
  • Axsome Therapeutics, Inc.$81
  • Teva Pharmaceuticals USA, Inc.$48
  • plus $62 from 2 others

What the payments were for

  • Food & beverage$1,097100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,097 in reported general payments places this provider in the 70th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$10,893
Medicare patients
24
Services billed
85

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine13$138,780
VraylarCariprazine Hcl14$34,782
Paliperidone ErPaliperidone19$4,116
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine63$3,575
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine91$3,112
Lurasidone Hcl23$3,093
Aripiprazole53$2,477
Methylphenidate ErMethylphenidate Hcl19$1,443
Atomoxetine Hcl18$1,351
Clonazepam88$1,231
Alprazolam140$977
Ziprasidone Hcl21$941
Doxepin Hcl21$778
Gabapentin43$745
Diazepam67$632

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$48$138,78013 claims
AbbVieVraylar$477$34,78214 claims
Almatica Pharma LLCSertraline Hcl$26$14627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →